Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer

Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a nasty disease with extremely high malignancy and poor prognosis. Annexin A3 (ANXA3) is a potential prognosis biomarker, displaying an excellent correlation of ANXA3 overexpression with patients' poor prognosis. Silencing the expression of ANXA3 effectiv...

Full description

Bibliographic Details
Main Authors: Yongxi Liang, Delin Min, Hulin Fan, Kunlin Liu, Juchuanli Tu, Xueyan He, Bingjie Liu, Lu Zhou, Suling Liu, Xun Sun
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Annexin A3 (ANXA3)
Degrader
Triple-negative breast cancer
Ubiquitination
Patient-derived xenograft
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522004907

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522004907

Similar Items